Literature DB >> 8225602

Immunomodulation of human peripheral blood mononuclear cell functions by defined lipid fractions of Mycobacterium avium.

W W Barrow1, J P de Sousa, T L Davis, E L Wright, M Bachelet, N Rastogi.   

Abstract

Mycobacterial fractions, some of which are associated with the cell envelope of Mycobacterium avium serovar 4, were assessed for their ability to affect various immunological functions of human peripheral blood mononuclear cells (PBM). Treatment of PBM with a total lipid fraction derived from M. avium serovar 4 resulted in a significant suppression of lymphoproliferative responsiveness to phytohemagglutinin stimulation at concentrations not affecting cell viability. Although a similar suppression was not observed when PBM were treated with purified serovar 4-specific glycopeptidolipids (GPL), treatment with the beta-lipid fragment derived from the GPL did result in a significant suppression of phytohemagglutinin responsiveness. Further studies revealed that the total lipid fraction and the beta-lipid fragment were effective at significantly reducing the ability of human macrophages to restrict the intracellular growth of mycobacteria and at stimulating PBM to secrete prostaglandin E2. These same effects were not observed when purified GPL or the reduced oligosaccharide fragment of the GPL was used. Other studies revealed that the total lipid and purified GPL fractions were effective at stimulating tumor necrosis factor alpha release from human PBM, whereas the beta-lipid fragment was not. These results indicate that mycobacterial lipids have various immunomodulatory capabilities, depending upon their chemical nature and ability to interact with certain host cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8225602      PMCID: PMC281313          DOI: 10.1128/iai.61.12.5286-5293.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  The measurement of transforming growth factor type beta (TGF beta) levels produced by peripheral blood mononuclear cells requires the efficient elimination of contaminating platelets.

Authors:  J Merino; J A Casado; J Cid; A Sánchez-Ibarrola; M L Subirá
Journal:  J Immunol Methods       Date:  1992-08-30       Impact factor: 2.303

2.  Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages.

Authors:  N Rastogi; V Labrousse; K S Goh; J P De Sousa
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

3.  Structural studies on the type-specific antigens and lipids of the mycobacterium avium. Mycobacterium intracellulare. Mycobacterium scrofulaceum serocomplex. Mycobacterium intracellulare serotype 9.

Authors:  P J Brennan; M B Goren
Journal:  J Biol Chem       Date:  1979-05-25       Impact factor: 5.157

4.  Comparison of in vitro cell cytotoxic assays for tumor necrosis factor.

Authors:  D A Flick; G E Gifford
Journal:  J Immunol Methods       Date:  1984-03-30       Impact factor: 2.303

5.  Analytical methods for thromboxane B2 measurement and validation of radioimmunoassay by gas liquid chromatography-mass spectrometry.

Authors:  H Sors; P Pradelles; F Dray; M Rigaud; J Maclouf; P Bernard
Journal:  Prostaglandins       Date:  1978-08

6.  Chronic infection due to Mycobacterium intracellulare in mice: association with macrophage release of prostaglandin E2 and reversal by injection of indomethacin, muramyl dipeptide, or interferon-gamma.

Authors:  C K Edwards; H B Hedegaard; A Zlotnik; P R Gangadharam; R B Johnston; M J Pabst
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

7.  Activities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against Mycobacterium avium.

Authors:  W W Barrow; E L Wright; K S Goh; N Rastogi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Comparative effects of Mycobacterium avium glycopeptidolipid and lipopeptide fragment on the function and ultrastructure of mononuclear cells.

Authors:  M Pourshafie; Q Ayub; W W Barrow
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

9.  Isolation and partial characterization of glycolipid fractions from Mycobacterium avium serovar 2 (Mycobacterium paratuberculosis 18) that inhibit activated macrophages.

Authors:  M E Hines; J M Jaynes; S A Barker; J C Newton; F M Enright; T G Snider
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

10.  Structure and antigenicity of the specific oligosaccharide hapten from the glycopeptidolipid antigen of Mycobacterium avium serotype 4, the dominant Mycobacterium isolated from patients with acquired immune deficiency syndrome.

Authors:  M McNeil; A Y Tsang; P J Brennan
Journal:  J Biol Chem       Date:  1987-02-25       Impact factor: 5.157

View more
  11 in total

1.  Use of Mono Mac 6 human monocytic cell line and J774 murine macrophage cell line in parallel antimycobacterial drug studies.

Authors:  E L Wright; D C Quenelle; W J Suling; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

2.  Lymphoproliferative responses to mitogens and prepared antigens of M. avium complex in patients with HIV infection.

Authors:  R M Novak; J Koirala; M L Sirdar; N D'Alfonso-Laghi; L Moreira; D L Pitrak; M Ghassemi
Journal:  J Clin Immunol       Date:  2000-01       Impact factor: 8.317

3.  Genetics of Capsular Polysaccharides and Cell Envelope (Glyco)lipids.

Authors:  Mamadou Daffé; Dean C Crick; Mary Jackson
Journal:  Microbiol Spectr       Date:  2014

4.  Immunomodulatory spectrum of lipids associated with Mycobacterium avium serovar 8.

Authors:  W W Barrow; T L Davis; E L Wright; V Labrousse; M Bachelet; N Rastogi
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

5.  T-cell lung granulomas induced by sepharose-coupled Mycobacterium tuberculosis protein antigens: immunosuppressive phenomena reversed with cyclophosphamide and indomethacin.

Authors:  R Hernández-Pando; H Orozco; R Mancilla
Journal:  Immunology       Date:  1995-12       Impact factor: 7.397

6.  Mannose receptor-dependent delay in phagosome maturation by Mycobacterium avium glycopeptidolipids.

Authors:  Lindsay Sweet; Prachi P Singh; Abul K Azad; Murugesan V S Rajaram; Larry S Schlesinger; Jeffrey S Schorey
Journal:  Infect Immun       Date:  2009-10-19       Impact factor: 3.441

7.  Potential drug targets for Mycobacterium avium defined by radiometric drug-inhibitor combination techniques.

Authors:  N Rastogi; K S Goh; E L Wright; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

Review 8.  The mycobacterial glycopeptidolipids: structure, function, and their role in pathogenesis.

Authors:  Jeffrey S Schorey; Lindsay Sweet
Journal:  Glycobiology       Date:  2008-08-22       Impact factor: 4.313

9.  Polyphasic taxonomic analysis establishes Mycobacterium indicus pranii as a distinct species.

Authors:  Vikram Saini; Saurabh Raghuvanshi; Gursaran P Talwar; Niyaz Ahmed; Jitendra P Khurana; Seyed E Hasnain; Akhilesh K Tyagi; Anil K Tyagi
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

10.  Utilization of a ts-sacB selection system for the generation of a Mycobacterium avium serovar-8 specific glycopeptidolipid allelic exchange mutant.

Authors:  Vida R Irani; Sun-Hwa Lee; Torsten M Eckstein; Julia M Inamine; John T Belisle; Joel N Maslow
Journal:  Ann Clin Microbiol Antimicrob       Date:  2004-09-30       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.